GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Immunovant Inc.
Immunovant develops drugs to treat autoimmune diseases. Its stock price reflects the potential of its lead antibody, batoclimab. The chart is a classic biotech story, with the company's value determined by expectations for key clinical trials.
Share prices of companies in the market segment - Pharma immune
Immunovant is a biotech company developing drugs to treat autoimmune diseases. We classify it as part of the immune pharmaceuticals sector, and the chart below reflects the general trends and investor sentiment in this biotech sector.
Broad Market Index - GURU.Markets
Immunovant is a biopharmaceutical company developing antibody-based therapies for the treatment of autoimmune diseases. Its innovative platform makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Immunovant compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
IMVT - Daily change in the company's share price Immunovant Inc.
The daily price change of Immunovant, a company developing drugs to treat autoimmune diseases, reflects the high volatility of the biotech sector. Change_co measures sensitivity to clinical trial results. On System.GURU.Markets, this metric is a key element in formulas evaluating binary risks and the potential for scientific breakthroughs.
Daily change in the price of a set of shares in a market segment - Pharma immune
Immunovant, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with IMVT, which focuses on autoimmune disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Immunovant is a biopharmaceutical company developing drugs to treat autoimmune diseases. Immunology is a cutting-edge but highly volatile segment of biotechnology. The chart below shows average daily fluctuations in this area, allowing you to assess Immunovant's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Immunovant Inc.
Immunovant is a biotech company working in the field of immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Annual dynamics of market capitalization of the market segment - Pharma immune
Immunovant, Inc. is a biotech company developing a new class of drugs for the treatment of autoimmune diseases. Its innovative platform has attracted considerable attention. Its stock price reflects the high potential of its technology and the risks associated with clinical trials, which are typical for the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Immunovant is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the key events are data releases, not macroeconomic statistics.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Immunovant Inc.
The performance of Immunovant, a biopharmaceutical company, depends on its R&D cycle. Monthly fluctuations on the chart reflect news about clinical trials of its drugs for autoimmune diseases, the success of which determines the potential of its innovative technology.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Immunovant is a biopharmaceutical company focused on developing drugs to treat autoimmune diseases. Its future depends on breakthrough results in clinical trials. The dynamics of the immunology segment of the pharmaceutical market on the chart will demonstrate the extent of investor confidence in this area, providing context for assessing the risks and potential rewards of investing in Immunovant.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Immunovant is a biotech company developing drugs to treat autoimmune diseases. Its performance is completely unrelated to the market. In the chart below, Immunovant shares move solely on news about clinical trials. The success or failure of its key molecule determines everything, making the company extremely volatile.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Immunovant Inc.
Shares of Immunovant, a biotech company focused on autoimmune diseases, are extremely news-sensitive. Weekly price movements reflect the release of clinical trial data and regulatory decisions. The chart below visualizes how short-term scientific developments and investor expectations trigger sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - Pharma immune
How unique is Immunovant's performance in the biotech sector? This chart compares the company's weekly stock price movements, driven by news about an autoimmune disease treatment, with the overall trend. This helps us understand whether the sharp stock price movement is the result of a unique scientific breakthrough or a reflection of general sentiment in this volatile industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Immunovant develops drugs to treat autoimmune diseases. Like many biotech companies, its shares are extremely sensitive to news. This chart shows how its weekly performance can be out of sync with the broader market, where movements are driven solely by clinical trial results.
Market capitalization of the company, segment and market as a whole
IMVT - Market capitalization of the company Immunovant Inc.
Immunovant, Inc.'s market cap is a bet on its antibody platform for treating autoimmune diseases. As a clinical-stage biotech, its valuation is entirely dependent on the success of its trials. The chart clearly demonstrates the high volatility typical of the sector, where news can either make or break investors.
IMVT - Share of the company's market capitalization Immunovant Inc. within the market segment - Pharma immune
Immunovant, Inc. develops drugs to treat autoimmune diseases. Its share of the biotech sector's market capitalization reflects the potential of its innovative therapeutic approach. The chart shows how investors view its scientific platform and clinical trial progress, which could lead to new treatment standards for many patients.
Market capitalization of the market segment - Pharma immune
The chart illustrates the combined market capitalization of biotech companies developing drugs to treat autoimmune diseases. Immunovant is a leader in the class of anti-FcRn therapies. The graph demonstrates the scale and competition in the market where the company is striving to create a breakthrough treatment.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart represents the market valuation of hope for patients with autoimmune diseases. Immunovant's market cap reflects the potential of its innovative platform to develop new treatments. The line shows how one promising technology can quickly gain traction in the global pharmaceutical industry.
Book value capitalization of the company, segment and market as a whole
IMVT - Book value capitalization of the company Immunovant Inc.
The book value of Immunovant, Inc., a clinical-stage biopharmaceutical company, is determined by its scientific potential. The chart below reflects the financial valuation of its intellectual property for innovative drugs for the treatment of autoimmune diseases. The dynamics illustrate how the company is investing in the development of its key asset—its therapeutic platform.
IMVT - Share of the company's book capitalization Immunovant Inc. within the market segment - Pharma immune
Immunovant's resources are not based on production lines, but rather on cutting-edge laboratories and clinical centers where innovative drugs for the treatment of autoimmune diseases are developed and tested. The chart reflects its share of the scientific infrastructure that underpins its therapeutic development.
Market segment balance sheet capitalization - Pharma immune
Immunovant is a clinical-stage biotech company. Its business is "lightweight" because it focuses on research and development rather than manufacturing facilities. Its main asset is its patents. The chart below illustrates how capital-intensive the pharmaceutical industry is overall and allows one to appreciate this R&D-focused model.
Book value of all companies included in the broad market index - GURU.Markets
Immunovant's assets are not factories, but capital, entirely focused on developing a single class of drugs for the treatment of a wide range of autoimmune diseases. Its book value reflects the financial strength dedicated to creating a potentially universal therapy for millions of patients.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Immunovant Inc.
Immunovant is another biotech focused on treating autoimmune diseases. Its book value is derived from research funding. Its market capitalization reflects investor confidence in the potential of its antibody platform. The chart shows how positive data from early clinical trials can generate billions of dollars in value long before sales.
Market to book capitalization ratio in a market segment - Pharma immune
Immunovant is a biopharmaceutical company focused on treating autoimmune diseases. Like many clinical-stage companies, its value is determined not by its assets, but by the potential of its scientific developments. The chart shows how highly the market values its promising technology.
Market to book capitalization ratio for the market as a whole
Immunovant is a biotech company developing therapies for autoimmune diseases. The chart shows how the market values this innovative drug discovery platform. The company's market capitalization, like many biotech companies, is not related to its physical assets but reflects investors' belief in the potential of its scientific developments to treat a wide range of diseases.
Debts of the company, segment and market as a whole
IMVT - Company debts Immunovant Inc.
Immunovant is a biopharmaceutical company focused on developing treatments for autoimmune diseases. For a company in clinical development, raising capital, including debt, is critical to funding research. This chart illustrates how the company secures resources for scientific breakthroughs.
Market segment debts - Pharma immune
Immunovant is a biopharmaceutical company developing drugs to treat autoimmune diseases. Their technology targets a broad range of conditions, offering significant market potential. This chart provides insight into the financial norms of the pharmaceutical industry, where R&D-stage companies raise significant capital to fund their ambitious clinical programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Immunovant Inc.
Immunovant is a biotech company specializing in developing treatments for autoimmune diseases. Its approach has the potential to transform therapy for millions of patients. This chart shows how the company is funding its cutting-edge, yet expensive, clinical trials using equity capital to achieve medical breakthroughs.
Market segment debt to market segment book capitalization - Pharma immune
Immunovant is a biopharmaceutical company focused on developing treatments for autoimmune diseases. This chart compares its debt, required to fund cutting-edge and risky research, to the overall market capitalization of the entire immune pharmaceutical sector. It demonstrates the company's significant stakes in the search for breakthrough therapies.
Debt to book value of all companies in the market
Immunovant develops drugs to treat autoimmune diseases. This chart compares its debt to the total book value of the entire economy. It shows how the innovative biotech company's financial needs compare to the overall market conditions that provide the capital for its expensive research.
P/E of the company, segment and market as a whole
P/E - Immunovant Inc.
This chart shows the valuation of Immunovant, Inc., a biopharmaceutical company specializing in the treatment of autoimmune diseases. For a clinical-stage company, value is determined by investor confidence in its scientific platform. The chart reflects how highly the market values the potential of its innovative therapeutic approaches.
P/E of the market segment - Pharma immune
This metric represents the average valuation for the biotech sector in which Immunovant operates. In this industry, filled with research-stage companies, the average earnings estimate is often uninformative. However, it does reflect the overall level of investor optimism regarding scientific breakthroughs and serves as a benchmark.
P/E of the market as a whole
Immunovant is a biopharmaceutical company developing innovative treatments for autoimmune diseases. The company's technology aims to reduce the level of harmful antibodies in the body. This risk-attitude chart helps understand how investors value companies at the forefront of immunology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Immunovant Inc.
Immunovant is a biotech company developing drugs to treat autoimmune diseases. Its future depends on the success of clinical trials. This chart reflects investor expectations regarding the potential of its innovative therapeutic platform. It is a bet that the company will be able to offer new solutions for complex diseases.
%20P%2FE%20Immunovant%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Immunovant-Inc.&v=1772625128414 "Chart of the company's future (projected) P/E Immunovant Inc.")
Future (projected) P/E of the market segment - Pharma immune
Immunovant is a clinical-stage biopharmaceutical company developing innovative treatments for autoimmune diseases. Its lead drug is an antibody designed to reduce levels of pathogenic immunoglobulins. This chart shows overall market sentiment toward the biotech sector, helping to assess Immunovant's potential in its important niche.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772625128431 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Immunovant is a biotech company developing innovative drugs for the treatment of autoimmune diseases. Like other clinical-stage companies in the sector, its value depends entirely on research results and investor confidence in its scientific platform, rather than on macroeconomic trends.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772625128442 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Immunovant Inc.
Immunovant, Inc. is a biopharmaceutical company developing drugs to treat autoimmune diseases. While in the clinical stage, the company focuses its resources on research and testing. This chart shows the financial costs associated with developing this innovative therapy, which has the potential to transform treatment approaches for a wide range of diseases.
Profit of companies in the market segment - Pharma immune
Immunovant, Inc. is a biopharmaceutical company developing antibodies for the treatment of autoimmune diseases. This chart shows the overall profitability of the immunology segment. Being in clinical development, the company contributes negatively to current overall profit, but its innovative platform could become the basis for a whole new class of drugs.
Overall market profit
Immunovant, Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases. Its future is determined by scientific results and regulatory approvals, not the state of the economy. This gross profit chart illustrates the macroeconomic backdrop against which Immunovant strives to create new standards of therapy for millions of patients.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Immunovant Inc.
Immunovant is a biopharmaceutical company developing drugs to treat autoimmune diseases. This chart reflects analysts' expectations for future earnings, based on the potential of its lead drug candidate to become a platform solution for a wide range of diseases. It demonstrates the market's confidence in the company's innovative approach to immunology.
%20profit%20of%20the%20company%20Immunovant%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Immunovant-Inc.&v=1772625128498 "Graph of future (projected) profit of the company Immunovant Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
Immunovant, Inc. is a biopharmaceutical company developing drugs to treat autoimmune diseases. This chart shows profitability forecasts for the immunology segment of the company. It reflects expectations for a new class of drugs that could offer more effective and convenient treatment for a wide range of conditions.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772625128540 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Immunovant, Inc. is developing therapies for autoimmune diseases. The company's success depends on the results of clinical trials. At the same time, the overall profit forecast, reflected in this chart, shapes the investment climate. Positive market sentiment facilitates raising the hundreds of millions of dollars needed to bring such complex and innovative drugs to market.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772625128611 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Immunovant Inc.
Immunovant, Inc. is a biopharmaceutical company developing therapeutics for autoimmune diseases. It has no revenue from clinical-stage sales. Its future P/S, following product launch, will be an indicator of the market's confidence in the potential of its innovative platform for treating a wide range of diseases.
P/S market segment - Pharma immune
Immunovant, Inc. is a biopharmaceutical company developing treatments for autoimmune diseases. Their lead drug candidate has potential for use across a broad range of diseases. Being in the clinical stage, its valuation reflects investors' confidence in this platform technology, as demonstrated by the chart compared to other biotechs.
P/S of the market as a whole
Immunovant develops drugs to treat autoimmune diseases. The company has no commercial revenue yet, and its value reflects the potential of its scientific platform. This chart, showing how the market values real revenue, clearly demonstrates that Immunovant's valuation is based solely on investors' faith in the future success of clinical trials.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Immunovant Inc.
Immunovant is a biotech company developing therapies for autoimmune diseases. Its valuation is based on the potential of its lead drug candidate. This chart represents the market's estimate of future revenue from the commercialization of this drug, which has potential to treat a wide range of conditions.
%20P%2FS%20Immunovant%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Immunovant-Inc.&v=1772625128842 "The graph of the company's future (projected) P/S Immunovant Inc.")
Future (projected) P/S of the market segment - Pharma immune
Immunovant, Inc. is a clinical-stage biopharmaceutical company developing antibodies for the treatment of autoimmune diseases. This chart shows how the market values the future potential of its innovative platform compared to other immunology companies. Its high valuation reflects high expectations for clinical success and a broad range of applications.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772625128890 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Immunovant develops drugs to treat autoimmune diseases. The company's technology has potential for use across a wide range of conditions. This chart shows overall investor revenue forecasts, and Immunovant illustrates how platform biotech companies, whose developments can be applied across multiple fields, are generating significant investor interest.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772625128921 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Immunovant Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of autoimmune diseases. Its revenue in this chart likely includes no revenue or is comprised of collaboration fees, as the company does not yet have approved or marketed products. Future sales growth will depend on the success of clinical trials.
Sales of companies in the market segment - Pharma immune
Immunovant is a biotech company developing therapies for autoimmune diseases. At this stage, its revenue is likely derived from partnerships with larger pharmaceutical companies. This chart allows investors to assess its financial stability and the industry's level of confidence in its scientific research.
Overall market sales
Immunovant, Inc. is a biopharmaceutical company developing treatments for autoimmune diseases. Its success depends entirely on progress in clinical trials and regulatory approvals. The macroeconomic trends reflected in this chart do not affect patient demand for the effective treatments Immunovant aims to provide.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Immunovant Inc.
Immunovant is a biopharmaceutical company developing drugs to treat autoimmune diseases. Its revenue forecast depends on the results of clinical trials and the future commercial potential of its innovative therapy. This chart shows analysts' confidence in its platform and the potential to create new treatment standards.
%20sales%20of%20the%20company%20Immunovant%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Immunovant-Inc.&v=1772625128990 "Schedule of future (projected) sales of the company Immunovant Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
Immunovant is a biopharmaceutical company developing drugs to treat autoimmune diseases. This chart shows projected revenue for the entire immunology segment. It allows investors to assess how large and rapidly growing analysts see this market, which is critical for the commercial prospects of Immunovant's innovative drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772625129030 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Immunovant is a biotech company developing drugs to treat autoimmune diseases. The company's success depends on the results of clinical trials. The overall economic situation, shown in this chart, influences the investment climate. Positive market expectations facilitate the raising of capital necessary to finance long-term and risky R&D projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772625129037 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Immunovant Inc.
Immunovant is a biopharmaceutical company developing drugs to treat autoimmune diseases. The chart below reflects its current focus on research. It doesn't show profit, but rather the efficiency of investing capital into clinical trials, the success of which determines the company's entire future value.
Market segment marginality - Pharma immune
Immunovant is a biopharmaceutical company developing drugs to treat autoimmune diseases using a new class of antibodies. This metric reflects market expectations for its innovative platform. Future high profitability will indicate the success of its approach and strong demand for new treatments.
Market marginality as a whole
Immunovant, Inc. is another biotech company focused on treating autoimmune diseases. Its value is based on expectations for future drugs. This chart, showing average returns across the economy, is merely a backdrop for high-risk but potentially extremely profitable biotech investments, where one success can change everything.
Employees in the company, segment and market as a whole
Number of employees in the company Immunovant Inc.
Immunovant is a biopharmaceutical company developing treatments for autoimmune diseases. The growth of its team of scientists and clinical development specialists is a direct indicator of progress in its research program. This chart allows us to assess how the company is increasing its resources to advance its candidates.
Share of the company's employees Immunovant Inc. within the market segment - Pharma immune
Immunovant, Inc. is a biopharmaceutical company developing innovative treatments for autoimmune diseases. This chart reflects its cutting-edge scientific approach. It shows the percentage of leading immunologists and researchers working on developing a new class of antibody therapeutics that could change the treatment paradigm that Immunovant brings together.
Number of employees in the market segment - Pharma immune
Immunovant, Inc. is a biopharmaceutical company developing treatments for autoimmune diseases. This chart shows employment in the immunology sector. The rapid growth of specialists in this field indicates significant progress in understanding the immune system and the development of a new class of targeted therapies, in which Immunovant aims to become a leader.
Number of employees in the market as a whole
Immunovant, Inc. is a biopharmaceutical company focused on treating autoimmune diseases. Its growing workforce of scientists and physicians is directly linked to the advancement of its drugs through clinical trials. This is an example of how targeted investments in biotechnology create jobs aimed at solving complex medical problems.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Immunovant Inc. (IMVT)
Immunovant is a biotech company developing drugs to treat autoimmune diseases. Like other companies in clinical development, their valuation is a measure of their scientific potential. This chart shows that the market highly values their intellectual capital. Billions of dollars in market capitalization, generated by a small team, are a bet on future success.
%20of%20the%20company%20Immunovant%20Inc.%20(IMVT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Immunovant-Inc.-IMVT&v=1772625129244 "Chart of market capitalization per employee (in thousands of dollars) of the company Immunovant Inc. (IMVT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Immunovant is a clinical-stage biotech developing therapies for autoimmune diseases. Like other R&D companies, its valuation reflects the hope for the future success of its drugs. This chart shows the industry average, helping to understand the significant premium investors are placing on the potential of this R&D team.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772625129255 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Immunovant is a biotech company developing drugs to treat autoimmune diseases. Its success depends entirely on the results of clinical trials. This chart reflects investors' faith that a small but highly qualified scientific team is capable of creating innovative therapies that could help millions of patients.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772625129280 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Immunovant Inc. (IMVT)
Immunovant is a biotech company developing drugs to treat autoimmune diseases. Their business is focused on research and clinical trials. They are not yet profitable. This chart shows the amount of investment burned per scientist and employee working on developing a new class of immunology drugs.
%20Chart%20Immunovant%20Inc.%20(IMVT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Immunovant-Inc.-IMVT&v=1772625129283 "Company Profit Per Employee (in thousands of dollars) Chart Immunovant Inc. (IMVT)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Immunovant is a clinical-stage biotech company specializing in the treatment of autoimmune diseases. This chart shows the benchmark for the "Biotech" sector. In this sector, the benchmark for profit per employee is typically *deeply negative*. Companies are burning through money on R&D (clinical trials) in anticipation of a future breakthrough.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772625129306 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Immunovant is a biotech company developing drugs (antibodies) for the treatment of autoimmune diseases. This is a complex R&D operation in immunology. This indicator, which shows the average contribution of one employee to profit, asks the question: how does Immunovant's immunology R&D sector compare to the overall market profitability per employee?
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772625129327 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Immunovant Inc. (IMVT)
Immunovant, Inc. is a biopharmaceutical company developing treatments for autoimmune diseases. This graph is typical for the industry at the research stage: there is no revenue per employee. It illustrates the company's scientific potential. Successful commercialization of the drug will lead to a sharp increase in this metric in the future, reflecting the value of innovation.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Immunovant-Inc.-IMVT&v=1772625129367 "Sales chart per company employee Immunovant Inc. (IMVT)")
Sales per employee in the market segment - Pharma immune
Immunovant is a biotech company developing drugs to treat autoimmune diseases. The company is in the clinical R&D phase. This chart shows the average revenue per employee in this segment. It serves as a productivity benchmark for commercial pharmaceutical companies and helps evaluate the effectiveness of the IMVT scientific team.
Sales per employee for the market as a whole
Immunovant (IMVT) is a biotech company specializing in autoimmune diseases. Like Viking, it is a clinical-stage R&D company. It has no revenue and is staffed by scientists. This metric currently reflects only expenses. Its future growth depends entirely on the success of clinical trials and regulatory approvals of its drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Immunovant Inc. (IMVT)
Immunovant is a biotech company developing drugs to treat autoimmune diseases. Their technology is promising but requires validation. This chart reflects the high risk inherent in this sector. "Short sellers" here are betting that clinical trials will not demonstrate the desired balance of efficacy and safety.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Immunovant-Inc.-IMVT&v=1772625129438 "Short Shares Chart for the Company Immunovant Inc. (IMVT)")
Shares shorted by market segment - Pharma immune
Immunovant is a biotech company developing therapies for autoimmune diseases. This chart highlights the pessimism in the immunology pharmaceutical sector. The rise in short positions across the industry reflects a general reluctance on the part of investors to take risks on companies whose drugs are still in early clinical trials and have uncertain prospects for success.
Shares shorted by the overall market
Immunovant (IMVT) is a biopharmaceutical company developing treatments for autoimmune diseases by inhibiting the FcRn receptor. This is a cutting-edge, but risky, field. This chart shows the overall level of market pessimism. When fear dominates the market, investors flee speculative biotechs. For IMVT, this means that market sentiment, not just science, can determine its ability to fund research.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Immunovant Inc. (IMVT)
Immunovant is a clinical-stage biotech focused on autoimmune diseases. Shares are sensitive to R&D news. This chart can surge above 70 on positive trial data. Oversold territory (<30) often reflects setbacks or concerns about funding/competition.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Immunovant-Inc.-IMVT&v=1772625129630 "RSI 14 indicator chart for the company's stock Immunovant Inc. (IMVT)")
RSI 14 Market Segment - Pharma immune
Immunovant is a biopharmaceutical company specializing in developing antibodies to treat autoimmune diseases. Its technology targets a wide range of disorders. This chart measures the overall momentum of the immunology biotech sector. It clearly shows when the entire niche is overheated by expectations or oversold by setbacks.
RSI 14 for the overall market
Immunovant (IMVT) is a biotech company. Like everything in its sector, it's critically dependent on this curve. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IMVT (Immunovant Inc.)
Immunovant (IMVT) is a biopharmaceutical company developing drugs (antibodies) for the treatment of autoimmune diseases. Their technology is aimed at reducing levels of pathogenic IgG antibodies. The chart shows the average price target, which reflects analysts' assessments of the potential of their lead drug (batoclimab) for the treatment of a variety of autoimmune disorders.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IMVT-Immunovant-Inc.&v=1772625129757 "A chart showing analyst consensus forecasts for the expected stock price. IMVT (Immunovant Inc.)")
The difference between the consensus estimate and the actual stock price IMVT (Immunovant Inc.)
Immunovant is a biotech company developing innovative anti-FcRn drugs for the treatment of a wide range of autoimmune diseases. This chart measures the gap between the current share price and the consensus target price. It shows how confident experts are in the success of their clinical trials and the potential of their platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IMVT-Immunovant-Inc.&v=1772625129766 "A chart showing the difference between the consensus forecast and the actual stock price. IMVT (Immunovant Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Immunovant is a biotech company developing anti-FcRn drugs for the treatment of a wide range of autoimmune diseases. This is one of the hottest areas of R&D. This chart shows analysts' overall expectations for the entire immunology sector. It reflects whether experts believe this class of drugs will be successful.
Analysts' consensus forecast for the overall market share price
Immunovant (IMVT) is an R&D biotech (part of Roivant) developing drugs for autoimmune diseases. They're burning through cash. This chart, reflecting expert expectations, is a measure of risk appetite for them. When the market is pessimistic, investors flee risky, pre-profitable biotechs, and IMVT struggles to attract capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Immunovant Inc.
Immunovant is a biotech company focused on developing therapeutics for autoimmune diseases. Their lead drug (batoclimab) is an anti-antibody targeting a broad spectrum of...
AKIMA Market Segment Index - Pharma immune
Immunovant (IMVT) is a clinical-stage biotech focused on autoimmune diseases; the company (controlled by Roivant) is developing a novel antibody (Batoclimab) for the treatment of a broad range of diseases. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does IMVT's platform R&D focus differentiate it from the average pharma company?
The AKIM Index for the overall market
Immunovant is a clinical-stage biotech company focused on autoimmune diseases. Its anti-FcRn technology is expected to become a platform for treating multiple diseases. This is a high-risk scientific bet. This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop for funding such companies.
